Evidence map›Paper›PMID 41026998›Full record

ArticleJournal of medicinal chemistry2025

Design of 2-Aminobenzothiazole Derivatives Targeting Trypanosomatid PTR1 by a Multidisciplinary Fragment Hybridization Approach.

Joanna Panecka-Hofman, Pasquale Linciano, Ina Pöhner, Edyta Dyguda-Kazimierowicz, Wiktoria Jedwabny, Giacomo Landi, Nuno Santarem, Gesa Witt, Bernhard Ellinger, Maria Kuzikov and 9 more

Abstract read
PubMed Full text at PMC Publisher
In one paragraph

Article in Journal of medicinal chemistry, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 1 paper.

0numbers the graph read from it
0cells of the map it votes in
1citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

1 citing paper in PubMed.

  1. Review
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

19 authors.

Joanna Panecka-HofmanMolecular and Cellular Modeling Group, Heidelberg Institute for Theoretical Studies (HITS), D-69118 Heidelberg, Germany.ORCID 0000-0003-4149-9090
Pasquale LincianoDepartment of Life Sciences, University of Modena and Reggio Emilia, 41121 Modena, Italy.ORCID 0000-0003-0382-7479
Ina PöhnerMolecular and Cellular Modeling Group, Heidelberg Institute for Theoretical Studies (HITS), D-69118 Heidelberg, Germany.ORCID 0000-0002-2801-8902
Edyta Dyguda-KazimierowiczFaculty of Chemistry, Wrocław University of Science and Technology, 50-370 Wrocław, Poland.ORCID 0000-0002-9154-5107
Wiktoria JedwabnyFaculty of Chemistry, Wrocław University of Science and Technology, 50-370 Wrocław, Poland.
Giacomo LandiDepartment of Biotechnology, Chemistry and Pharmacy, University of Siena, 53100 Siena, Italy.
Nuno SantaremInstituto de Investigação e Inovação em Saúde, Universidade do Porto and Institute for Molecular and Cell Biology, 4150-180 Porto, Portugal.
Gesa WittFraunhofer Institute for Translational Medicine and Pharmacology ITMP, Discovery Research ScreeningPort, D-22525 Hamburg, Germany.
Bernhard EllingerFraunhofer Institute for Translational Medicine and Pharmacology ITMP, Discovery Research ScreeningPort, D-22525 Hamburg, Germany.
Maria KuzikovFraunhofer Institute for Translational Medicine and Pharmacology ITMP, Discovery Research ScreeningPort, D-22525 Hamburg, Germany.
Rosaria LucianiDepartment of Life Sciences, University of Modena and Reggio Emilia, 41121 Modena, Italy.
Stefania FerrariDepartment of Life Sciences, University of Modena and Reggio Emilia, 41121 Modena, Italy.ORCID 0000-0003-1149-5953
Daniele AielloDepartment of Life Sciences, University of Modena and Reggio Emilia, 41121 Modena, Italy.
Stefano ManganiDepartment of Biotechnology, Chemistry and Pharmacy, University of Siena, 53100 Siena, Italy.ORCID 0000-0003-4824-7478
Cecilia PozziDepartment of Biotechnology, Chemistry and Pharmacy, University of Siena, 53100 Siena, Italy.ORCID 0000-0003-2574-3911
Anabela Cordeiro-da-SilvaInstituto de Investigação e Inovação em Saúde, Universidade do Porto and Institute for Molecular and Cell Biology, 4150-180 Porto, Portugal.
Sheraz GulFraunhofer Institute for Translational Medicine and Pharmacology ITMP, Discovery Research ScreeningPort, D-22525 Hamburg, Germany.ORCID 0000-0003-2543-1643
Maria Paola CostiDepartment of Life Sciences, University of Modena and Reggio Emilia, 41121 Modena, Italy.
Rebecca C WadeMolecular and Cellular Modeling Group, Heidelberg Institute for Theoretical Studies (HITS), D-69118 Heidelberg, Germany.ORCID 0000-0001-5951-8670

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

Pteridine reductase 1 (PTR1) is a folate pathway enzyme essential for pathogenic trypanosomatids and a promising drug target for diseases such as sleeping sickness and leishmaniasis. Previous studies have shown that the 2-aminobenzothiazole moiety targets the PTR1 biopterin pocket, while 3,4-dichlorophenyl-containing compounds, such as

Indexed as

BenzothiazolesDrug DesignEnzyme InhibitorsOxidoreductasesProtozoan ProteinsTrypanocidal AgentsTrypanosoma brucei bruceiLeishmania infantumLeishmania majorParasitic Sensitivity TestsStructure-Activity Relationshipaminobenzothiazole compoundBenzothiazolesEnzyme InhibitorsOxidoreductasesProtozoan Proteinspteridine reductaseTrypanocidal Agents

Identifiers

PMID41026998
PMCPMC12516686

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.